AN2 Therapeutics grants CMO Cameron Trenor options for 233,333 shares at USD 5.36 each
ANTX•Inducement equity awards for new CMO
AN2 Therapeutics set inducement equity awards for new Chief Medical Officer Cameron Trenor with a Sept. 15, 2026 grant date.
- Package includes a non-qualified stock option for 233,333 shares priced at USD 5.36, equal to the closing share price.
- Option runs 10 years; 25% vests Aug. 24, 2026, with the remaining shares vesting monthly over three years.
- Also granted 116,667 restricted stock units; 10,400 vest Jan. 1, 2027, with the balance vesting in three annual installments from Jan. 1, 2028.
